Primary Care Clinics in Concord, CA Accepting Medicare
32 Primary Care Clinics found. Showing 21 - 32
 Charles Renner, Md Clinic/Center - Primary Care Medicare: Not Enrolled in Medicare Practice Location: 5161 Clayton Rd, Suite C, Concord, CA 94521 Phone: 925-687-2200 Fax: 925-689-5608 |
Parham Gharagozlou Md Inc Internal Medicine Medicare: Medicare Enrolled Practice Location: 3108 Willow Pass Rd, Concord, CA 94519 Phone: 925-849-6634 Fax: 925-849-6635 |
Imran A. Khan, M.d., Inc. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1455 Galindo St Apt 2356, Concord, CA 94520 Phone: 530-510-1758 |
J. Arias Medical Corporation Internal Medicine Medicare: Medicare Enrolled Practice Location: 2211 East St, Concord, CA 94520 Phone: 925-603-1363 |
Gastroenterology Medical Group, Inc. Internal Medicine - Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 2415 High School Ave, Suite 100, Concord, CA 94520 Phone: 925-687-9650 Fax: 925-685-8447 |
Pg&e Health Centers Clinic/Center - Multi-Specialty Medicare: Not Enrolled in Medicare Practice Location: 1850 Gateway Blvd, Concord, CA 94520 Phone: 628-201-3555 |
Ketamine Infusion Associates, Inc. Clinic/Center Medicare: Not Enrolled in Medicare Practice Location: 2975 Treat Boulevard, Suite Number B-1, Concord, CA 94518 Phone: 925-357-9033 Fax: 925-357-9036 |
I-ma Acupuncture Inc Clinic/Center Medicare: Not Enrolled in Medicare Practice Location: 2485 High School Ave Ste 123, Concord, CA 94520 Phone: 408-876-9217 |
Park Avenue Walk In Clinic Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1280 Monument Blvd Ste 1, Concord, CA 94520 Phone: 925-825-8181 Fax: 925-825-8383 |
Concentra Urgent Care Clinic/Center Medicare: Not Enrolled in Medicare Practice Location: 1855 Gateway Blvd Ste 100, Concord, CA 94520 Phone: 925-685-7744 Fax: 925-685-0462 |
Planned Parenthood Shasta Diablo Inc Clinic/Center - Community Health Medicare: Medicare Enrolled Practice Location: 2185 Pacheco St, Concord, CA 94520 Phone: 925-676-0300 |
Stephen B. Lewis, M.d., Inc. Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 2425 East St, Suite 15, Concord, CA 94520 Phone: 925-682-9232 Fax: 925-672-2198 |
News Archive
Placentophagia may offer benefits to human mothers
A paper by neuroscientists at the University at Buffalo and Buffalo State College suggests that ingestion of components of afterbirth or placenta - placentophagia - may offer benefits to human mothers and perhaps to non-mothers and males.
Simplified mathematical model to study spread of dengue fever in urban areas
Mathematics is often implemented in healthcare and medical research. From health management to the bio-pharmaceutical fields, math modeling can be used to predict the spread of diseases, how to prevent epidemics and so much more.
Quest Diagnostics' OVA1 ovarian cancer test cleared by the FDA
The U.S. Food and Drug Administration (FDA) today cleared the OVA1(TM) Test, the first blood test that, prior to surgery, can help physicians determine if a woman is at risk for a malignant pelvic mass. OVA1 is the first FDA-cleared laboratory test that can indicate the likelihood of ovarian cancer with high sensitivity prior to biopsy or exploratory surgery, even if radiological test results fail to indicate malignancy.
Industry funded studies on breast cancer treatments more likely to have positive results
Industry-funded clinical trials of breast cancer medications report more favorable results than nonindustry supported research, according to a study published in the Feb. 26 online edition of the journal Cancer, the New York Times reports (Bakalar, New York Times, 2/27).
Ranbaxy obtains FDA approval to manufacture, market Fenofibrate Capsules USP, 43 mg and 130 mg
Ranbaxy Laboratories Limited announced today that the Company has received approval from the U.S. Food and Drug Administration to manufacture and market Fenofibrate Capsules USP, 43 mg and 130 mg. The Office of Generic Drugs, U.S. Food and Drug Administration, has determined the Ranbaxy formulations to be bioequivalent and have the same therapeutic effect as that of the reference listed drug Antara Capsules, 43 and 130 mg, respectively, of Lupin Atlantis.
› Verified 2 days ago
- 1
- 2(current)